Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen

Patent metadata

Field	Value
Publication number	US-10799577-B2
Application number	US-201815892330-A
Country	US
Kind code	B2
Filing date	Feb 8, 2018
Priority date	Feb 15, 2012
Publication date	Oct 13, 2020
Grant date	Oct 13, 2020

Abstract

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.

First claim

The invention claimed is:

1. A nucleic acid molecule comprising:
a) a coding region, encoding at least one peptide or protein;
b) at least one histone stem-loop; and
c) a poly(A) sequence or a polyadenylation signal;

wherein said peptide or protein comprises a pathogenic antigen or an antigenic fragment thereof, wherein the antigen is an antigen from respiratory syncytial virus.

2. The nucleic acid molecule of claim 1 , where the antigen from respiratory syncytial virus is selected from fusion protein F, nucleoprotein N, matrix protein M, matrix protein M2-1, matrix protein M2-2, phosphoprotein P, small hydrophobic protein SH, major surface glycoprotein G, polymerase L, non-structural protein 1 NS1, and non-structural protein 2 NS2.

3. The nucleic acid molecule of claim 1 , where the antigen from respiratory syncytial virus is from the fusion protein F.

4. The nucleic acid molecule of claim 1 , wherein the at least one histone stem loop is heterologous to the coding region encoding the at least one peptide or protein.

5. The nucleic acid molecule of claim 1 , wherein the fragment of the antigenic protein or peptide retains at least 50% of the biological activity of the naturally occurring full-length antigenic protein or peptide.

6. The nucleic acid molecule of claim 1 , wherein the antigenic protein or peptide comprises an antigenic protein fragment comprising at one antigenic epitope.

7. The nucleic acid molecule of claim 1 , wherein the at least one histone stem-loop encodes a RNA that specifically binds to stem-loop binding protein (SLBP).

8. The nucleic acid molecule of claim 1 , wherein the at least one histone stem-loop does not comprise a histone downstream element (HDE).

9. The nucleic acid molecule of claim 1 , wherein the coding region does not encode a reporter protein, marker, or selection protein.

10. The nucleic acid molecule of claim 1 , wherein the nucleic acid is an RNA.

11. The nucleic acid molecule of claim 10 , wherein the nucleic acid molecule further comprises a 5′ cap structure.

12. The nucleic acid molecule of claim 1 , wherein the poly(A) sequence comprises a sequence of about 25 to about 400 adenosine nucleotides.

13. The nucleic acid molecule of claim 1 , wherein the polyadenylation signal comprises the consensus sequence NN(U/T)ANA.

14. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises a sequence of at least 10 consecutive cytidines.

15. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises a stabilizing sequence from the alpha globin 3′ UTR.

16. The nucleic acid molecule of claim 1 , wherein the nucleic acid sequence is modified from the wild-type molecule such that the G/C content of the coding region is increased compared with the G/C content of the coding region of the wild-type nucleic acid.

17. A method of treating a subject who has, or is likely to contract, RSV, comprising administering to the subject a therapeutically effective amount of the nucleic acid molecule of claim 1 .

18. A pharmaceutical composition comprising the nucleic acid molecule of claim 1 and a pharmaceutically acceptable carrier.

19. The pharmaceutical composition of claim 18 , wherein the composition further comprises a cationic or polycationic compound in complex with the nucleic acid molecule.

20. The pharmaceutical composition of claim 19 , wherein the composition further comprises a cationic or polycationic proteins, peptides, polymers, polysaccharides or lipids in complex with the nucleic acid molecule.

21. A nucleic acid vaccine for the treatment or prevention of a RSV infection, comprising the nucleic acid molecule of claim 1 .

22. A method for increasing the expression of an antigenic peptide or protein comprising administering the nucleic acid of claim 1 to a cell-free expression system, a cell, a tissue or an organism.

Assignees

• Curevac Ag

Inventors

• Thess Andreas
• Schlake Thomas
• Probst Jochen

Classifications

• A61K39/00 Primary

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C12N15/68

  Stabilisation of the vector · CPC title

• C12N2770/20034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K39/12

  Viral antigens · CPC title